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Birc2 (cIap1) regulates endothelial cell integrity and
blood vessel homeostasis
Massimo M Santoro1,2, Temesgen Samuel3,4, Tracy Mitchell1,5, John C Reed3 & Didier Y R Stainier1
Integrity of the blood vessel wall is essential for vascular
homeostasis and organ function1,2. A dynamic balance between
endothelial cell survival and apoptosis contributes to this
integrity during vascular development and pathological
angiogenesis3–6. The genetic and molecular mechanisms
regulating these processes in vivo are still largely unknown.
Here, we show that Birc2 (also known as cIap1) is essential
for maintaining endothelial cell survival and blood vessel
homeostasis during vascular development. Using a forward-
genetic approach, we identified a zebrafish null mutant for
birc2, which shows severe hemorrhage and vascular regression
due to endothelial cell integrity defects and apoptosis. Using
genetic and molecular approaches, we show that Birc2
positively regulates the formation of the TNF receptor complex
I in endothelial cells, thereby promoting NF-jB activation and
maintaining vessel integrity and stabilization. In the absence of
Birc2, a caspase-8–dependent apoptotic program takes place
that leads to vessel regression. Our findings identify Birc2 and
TNF signaling components as critical regulators of vascular
integrity and endothelial cell survival, thereby providing an
additional target pathway for the control of angiogenesis and
blood vessel homeostasis during embryogenesis, regeneration
and tumorigenesis.
Vascular development is regulated by proangiogenic and antiangio-
genic factors in the immediate environment of endothelial cells.
A positive balance of angiogenic factors stimulates endothelial cell
proliferation, migration and survival, leading to the formation of new
vessels, whereas a prevalence of antiangiogenic factors shifts the
equilibrium to vessel quiescence or, under certain circumstances, to
endothelial cell apoptosis and vessel regression5,6. Abnormalities in the
control of these processes can contribute to embryonic death and to a
variety of vascular and immune diseases (for example, diabetic
retinopathies, atherosclerosis and systemic lupus erythematosus)3,4,7,8.
Thus, elucidation of the genetic control of endothelial cell survival and
apoptosis is critical to better understanding vascular biology and
endothelial angiogenesis in normal and pathological conditions.
To identify the molecular pathways involved in endothelial cell
survival and vascular homeostasis, we used a forward genetic approach
in zebrafish, a model organism that has a number of advantages for
investigating vascular development and homeostasis9. In the course of
a large-scale N-ethyl-N-nitrosourea mutagenesis screen for vascular
mutants10, we identified the mutation tomato (tom). The tom muta-
tion is recessive and shows complete penetrance and expressivity. tom
mutants show distinct vascular hemorrhage and blood pooling in
several tissues in the context of a wild-type body morphology
(Fig. 1a,b). To examine whether the hemorrhage is associated with
vascular defects, we crossed the mutation into the Tg(flk1:GFP)s843
line, a transgenic line expressing the green fluorescent protein (GFP)
in endothelial cells throughout the developing vasculature10. Fluores-
cence microscopy analyses showed that the hemorrhagic phenotype in
tom mutants was accompanied by specific blood vessel regression
starting between 54 and 60 hours post-fertilization (hpf) (Fig. 1c,d
and Supplementary Fig. 1 online). Endothelial regression and cell
fragmentation were observed in the brain and trunk vasculature of tom
mutants (Fig. 1e and Supplementary Movie 1 online).
To test whether the vascular regression was due to apoptotic cell
death, we examined the expression of apoptotic markers in wild-type
and tom mutant embryos (Fig. 1f–m). Indeed, endothelial cells in tom
mutants were positive for active caspase-3 and TUNEL staining, and
showed typical morphological features of apoptotic cells at this stage.
Notably, no other embryonic tissues showed specific apoptosis. These
data indicate that the apoptotic program is activated specifically in
endothelial cells in tom mutant embryos and suggest that tom may
regulate endothelial cell survival and vascular integrity.
By positional cloning, we determined that tom encodes baculoviral
IAP repeat-containing protein-2, Birc2 (also called cIap1, cellular
inhibitor of apoptosis 1) (Fig. 2a). Sequence analysis showed that
the tom mutant allele contains a nonsense mutation in birc2 that
introduces a premature stop codon in the protein at amino acid
position 29, likely generating a null allele (Fig. 2b). To further test
whether Birc2 regulates vascular integrity, we knocked down Birc2
expression using an antisense morpholino oligonucleotide. birc2
morphants showed the hemorrhagic phenotype and vascular apoptosis
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observed in tom mutants (Supplementary Fig. 2 online). Using a
specific Birc2 antibody, we carried out immunoblot analyses on
protein lysates from wild-type and tom mutant embryos, as well
as birc2 morphants (Fig. 2c). We found that tom mutants and
birc2 morphants did not express detectable levels of Birc2. Together,
these results indicate that tom is a null mutation in birc2 and that
Birc2 regulates endothelial cell survival and vascular integrity in
zebrafish embryos.
To further understand Birc2 function, we analyzed Birc2 expression
in developing zebrafish embryos. By in situ hybridization, we detected
birc2 transcripts in the vasculature starting at 48 hpf (Supplementary
Fig. 3a,b online). By immunoblot analyses of embryo lysates, we
observed that Birc2 expression begins by 54 hpf (Fig. 2d). By
immunofluorescence analyses, we detected Birc2 protein specifically
in the vasculature also starting at 54 hpf (Fig. 2e–m). Birc2 is present
in the cytosol of endothelial cells but not in their nuclei (Supplemen-
tary Fig. 3c–e). This temporal expression pattern of Birc2 correlates
with the onset of vascular apoptosis and regression that is detectable in
tom mutants starting between 54 and 60 hpf.
Genomic and phylogenetic analyses reveal that—in contrast to
mammalian genomes, which contain two closely related BIRC genes
called BIRC2 (cIAP1) and BIRC3 (cIAP2)—lower-vertebrate genomes
contain only one birc2 (ciap1) gene. This finding highlights the
usefulness of the zebrafish model, and the tom mutant in particular,
in exploring the functional role of birc2 in vivo. Birc2 belongs to a
family of inhibitor of apoptosis proteins (IAPs): members of this
family regulate apoptosis induced by various stimuli11. Mammalian
BIRC2 and BIRC3 have been identified as components of the tumor
necrosis factor receptor (TNFR) signaling complex through binding to
TNFR-associated factor 2 (TRAF2)12,13. TNFR belongs to the super-
family of death receptors and regulates numerous cellular functions,
including cell survival and differentiation and apoptosis14–16. TNFR
activates cell survival and differentiation or apoptosis by assembling
two molecularly and spatially distinct signaling complexes. Within a
few minutes of TNF binding to TNFR, a plasma membrane–bound
signaling complex, termed complex I, forms. This complex contains
the receptor itself, receptor interacting protein 1 (RIP1), TRAF2,
BIRC2, BIRC 3 and the TNFR-associated death domain (TRADD).
Complex I initiates signals that lead to the rapid activation of NF-kB
through polyubiquitination of NF-kB essential modulator (NEMO)
and recruitment of the IKK ‘signalsome’. Later on, possibly during
receptor internalization, TRADD and RIP1 dissociate from the recep-
tor and recruit fas-associated via death domain (FADD) and caspase-8
into a secondary complex, called complex II, that mediates caspase-8
activation and cell death17.
To investigate whether zebrafish Birc2 modulates endothelial cell
survival by regulating TNFR signaling, we first tested whether zebra-
fish Birc2 can bind TRAF2. To this end, we performed TRAF2 co-
immunoprecipitation assays using HEK293 cell lines expressing zebra-
fish Birc2. Zebrafish Birc2, but not Birc4 (another member of the IAP
family and potent inhibitor of effector caspases18), binds endogenous
mammalian TRAF2 (Fig. 3a). We also found that zebrafish Traf2 can
bind Birc2 (Supplementary Fig. 4 online), indicating that the
mechanisms of TRAF2 and Birc2 interactions are conserved among
different vertebrate species. Thus, we investigated whether Birc2 could
regulate endothelial cell survival in a TRAF2-dependent manner by
engineering a Birc2 point mutant, called Birc2-E66A/R67A, which
renders Birc2 defective for TRAF2 binding (owing to a GluArg-
AlaAla mutation in BIR1 domain)19. Recent studies indicate that
recruitment of Birc2 to complex I through TRAF2 interaction pro-
motes NEMO polyubiquitination and subsequent NF-kB activation
via the E3-ubiquitin ligase activities in the complex20,21. Therefore, we
also generated a second mutant, called Birc2-H617A, that renders
Birc2 defective in its E3-ubiquitin ligase activity (owing to a His-Ala
mutation in its RING domain)19,22. We first confirmed by in vivo
expression that these Birc2 variants were defective in TRAF2 binding
(the E66A/R67A mutant) and in ubiquitin ligase activity (the H617A
mutant) (Supplementary Fig. 4). We then tested whether the variants
could rescue the tom mutant phenotype (Fig. 3b). Although wild-type
Birc2 rescued the phenotype, the mutant constructs did not rescue the
vascular apoptosis and hemorrhagic phenotypes in tom mutants,
suggesting that both the TRAF2-binding and E3-ligase activity of
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b Figure 1 Vascular integrity and endothelial survival are defective in tom
mutants. (a,b) Wild-type (WT) and tomato (tom) mutant embryos at 60 hpf.
Vascular hemorrhage is visible at several locations in tom mutants (arrows).
(c,d) Bright-field (c) and fluorescent (d) micrographs of head vasculature in
Tg(flk1:GFP)s843 WT and tom mutant embryos at 60 hpf. tom mutants show
hemorrhage (arrowhead) due to vascular integrity defects and regression
(arrows) as detectable in the Tg(flk1:GFP)s843 background. (e) Confocal
projections of WT and tom mutant embryo head vasculature (dorsal view,
anterior to the bottom) showing endothelial breakdown and regression in tom
mutants, in particular in the hindbrain (arrowhead) and eye capillary network
(arrow) at 60 hpf. (f–m) Confocal transverse sections of Tg(flk1:GFP)s843 WT
(f,h,j,l) and tom mutant (g,k,i,m) embryos stained for DNA (blue), active
caspase-3 (red; f–i) or TUNEL (red; j–m) at 60 hpf. Endothelial cells in tom
mutants are positive for active caspase-3 and TUNEL. No other embryonic
tissues show specific apoptosis in tom mutants; however, some TUNEL-
positive cells are visible in the skin of both WT and tom mutant embryos
(j–k). h,i,l and m show a magnification of the areas outlined in f,g,j and k,
respectively. Endothelial cells within the dorsal aorta and posterior cardinal
vein are positive for active caspase-3 and TUNEL (arrows), and feature cell
fragmentation, characteristic of cells undergoing programmed cell death.
Sections shown are at the level of the tenth somite. NT, neural tube; NC,
notochord; DA, dorsal aorta; PCV, posterior cardinal vein. Scale bars, 20 mm.
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Birc2 are critical in promoting endothelial cell survival. These data
suggest that Birc2 regulates endothelial cell survival in vivo by
modulating TRAF2-dependent signaling and, possibly, by ubiquitinat-
ing target proteins in the TNFR-associated complex, such as NEMO
and TRAF221.
Impairment of complex I formation and signaling promotes TNFR-
dependent complex II formation and subsequent apoptosis17. To test
whether Birc2 is required to prevent TNFR-mediated formation of
complex II (and thus, caspase-8 activation), we depleted endogenous
BIRC2 and BIRC3 in human primary endothelial cells (HUVECs) with
siRNAs. siRNAs specific for BIRC2 and BIRC3 reduced expression of
their respective proteins (Fig. 3c). Cells were then stimulated with
TNFa, and protein lysates from the stimulated cells were tested for
procaspase-8 by immunoblotting (Fig. 3d). We observed that com-
pared to control-transfected cells, cells depleted of BIRC2 and BIRC3
showed greater procaspase-8 cleavage and activation upon TNFa
exposure. These data suggest that in endothelial cells exposed to
certain extracellular stimuli, the absence of BIRC2 and BIRC3 can
promote a caspase-8–dependent apoptotic program, possibly
mediated by complex II formation. Following these observations, we
hypothesized that endothelial cell apoptosis in tom mutants could be
initiated by complex II formation and caspase-8 activation. To test this
hypothesis, we overexpressed Casp8 and FADD-like apoptosis regu-
lator (Cflar), a potent inhibitor of caspase-8, in tom mutants. Cflar
binds to FADD and caspase-8 through a homotypic interaction and
blocks caspase-8 recruitment into complex II and its subsequent
activation16,23,24. Cflar overexpression rescued endothelial cell death
in tom mutants (Fig. 3e). These data indicate that endothelial cell
apoptosis in tom mutants is associated with caspase-8 activation and
possibly TNFR signaling. To further test this hypothesis, we treated
tom mutants with a cell-permeable caspase-8–specific inhibitor, IETD-
fmk. This treatment also rescued endothelial cell death in tom mutants
(Supplementary Fig. 5 online), supporting the hypothesis that
caspase-8 activation may mediate endothelial cell apoptosis and vessel
regression in tom mutants. Because there is no evidence that BIRC2 or
BIRC3 suppresses caspases directly25, we hypothesize that Birc2 most
likely functions by preventing apoptosis promoted by formation of the
TNFR-mediated complex II.
One of the main signaling pathways activated by TNFR through
complex I is the IKK–NF-kB pathway. This pathway blocks complex II
formation through Cflar expression26,27. To further test the hypothesis
that Birc2 may promote TNFR-dependent complex I formation in
endothelial cells, we examined whether Birc2 was required for TNFR-
mediated NF-kB activation by analyzing the IKK–NF-kB signaling
pathway in HUVECs deficient in both BIRC2 and BIRC3. Cells
transfected with BIRC2 and BIRC3 siRNAs had a reduction in
IKKa, IKKb and NF-kB phosphorylation and activation in response
to TNFa stimulation (Fig. 4a). As a control, these cells were also
stimulated with IL1b, a cytokine known to induce NF-kB activation
through a signaling complex other than TNFR complex I28. Unlike
TNFa, IL1b stimulation resulted in equivalent levels of IKKa and b
and NF-kB activation in BIRC2- and BIRC3-deficient and control
cells, suggesting that Birc2 specifically promotes TNFR-dependent
complex I formation and NF-kB activation in endothelial cells. We
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Figure 2 tom encodes Birc2. (a) Genetic map of the tom region. Numbers
below the line indicate the number of recombinants at the corresponding
SSLP markers (shown above the line). The birc2 locus is depicted by a red
bar next to the flanking marker z7809 identified by analysis of 1,240
diploid mutants. Below the birc2 locus is the BAC genomic clone (DKEYP-
69C1) identified in the chromosomal walk. (b) The Birc2 protein contains
several domains including three BIR domains, a CARD domain and a RING
domain. The toms805 allele bears an A-T base change that introduces a
stop codon at amino acid 29 leading to an early truncation of the Birc2
protein. (c) Immunoblot analyses of protein extracts from 80-hpf larvae
showing that tom mutants and birc2 morphants do not contain a detectable
level of Birc2 protein. Anti-tubulin immunoblot serves as protein control for
loading. (d) Time-course analysis of Birc2 expression in zebrafish. Immunoblot analyses of protein extracts from 30-, 54- and 80-hpf embryos showing that
Birc2 expression begins by 54 hpf. Anti-tubulin immunoblot serves as protein control for loading. (e–j) Confocal transverse sections of Tg(flk1:GFP)s843
embryos at 30 (e–g), 54 (h–j) and 80 (k–m) hpf stained for Birc2 (red). Birc2 is expressed and co-localizes with GFP-positive endothelial cells starting at
54 hpf. Sections shown are at the level of the 18th somite. NT, neural tube; NC, notochord; DA, dorsal aorta; PCV, posterior cardinal vein. Scale bars, 20 mm.
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further assessed whether loss of BIRC2 and BIRC3 expression corre-
lates with endothelial cell apoptosis. BIRC2- and BIRC3-deficient
HUVEC cells stimulated with TNFa showed a specific apoptotic
phenotype (Supplementary Fig. 6 online), confirming that impair-
ment of TNFR complex I promotes an apoptotic response in
endothelial cells.
NF-kB signaling regulates endothelial cell integrity and vascular
homeostasis29,30. We thus examined whether NF-kB signaling regu-
lates vessel development in zebrafish by treating embryos with two
different NF-kB inhibitors, NF-kB activation inhibitor (NAI)
(Fig. 4b–d and Supplementary Movie 2 online) and BAY11-7082
(data not shown). Confirming the essential function of NF-kB acti-
vation in vascular homeostasis, chemical inhibition of NF-kB acti-
vation provoked vascular leakage, hemorrhage and vascular regression
in zebrafish embryos. We obtained the same phenotype by inhibiting
the upstream IKKa–IKKb complex with the
specific IKK kinase inhibitor wedelolactone
(data not shown). Notably, endothelial differentiation was not affected
in NAI-treated embryos as assessed by the expression of the arterial-
specific marker EphrinB2a and the venous-specific marker flt4 (data
not shown). Additionally, confocal microscopy analyses of NAI-
treated and tom mutant embryos indicated that NF-kB inhibition
altered vessel morphology of the dorsal aorta and cardinal vein
(Supplementary Fig. 7 online). The absence of cell death in NAI-
treated embryos suggests that the vascular leakage and integrity defects
observed in tom mutants precede endothelial cell death.
To further test the genetic link between birc2 and the IKK–NF-kB
pathway, we overexpressed zebrafish NEMO in tom mutants. NEMO
overexpression, which is required for NF-kB activation, can rescue
endothelial cell death in tom mutants (Fig. 4e), providing further
evidence that birc2 mutants have defects in NF-kB activation. In
summary, NF-kB inhibition and Birc2 deficiency in zebrafish alter
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Figure 3 Birc2 regulates TNFR-TRAF2 signaling and death receptor–mediated caspase-8 activation in endothelial cells. (a) Co-immunoprecipitation of
TRAF2 with zebrafish Birc2 in HEK293T cells. Above, TRAF2 co-immunoprecipitates with transfected zebrafish Birc2 and human BIRC2, but not zebrafish
Birc4. Upper bands are IgG. Below, TRAF2 expression in whole cell lysates. (b) Embryos from toms805 heterozygote intercrosses injected at the one-cell
stage with the indicated amount of mRNA encoding Birc2, Birc2-E66A/R67A or Birc2-H617A. Histogram shows the percentage of tom mutants identified
72 hpf after injection. Birc2, but not Birc2-E66A/R67A or Birc2-H617A, rescued tom mutants in a dose-dependent manner. Error bars, s.d. (c) BIRC2/3
expression in siRNA-transfected HUVECs. Transfection of specific siRNA for BIRC2 and BIRC3 (BIRC2/3 siRNA) reduces endogenous BIRC2/3 expression
in HUVECs. (d) Knock-down of BIRC2/3 promotes a TNFa-dependent activation and degradation of procaspase-8 in HUVECs. siRNA-transfected cells were
stimulated with TNFa for 1 h and evaluated for procaspase-8 cleavage and activation. Anti-tubulin immunoblot serves as protein control for loading.
(e) Embryos from toms805 heterozygote intercrosses injected at the one-cell stage with the indicated amount of mRNA encoding Cflar. Histogram shows the
percentage of tom mutants identified 72 hpf after injection. Cflar rescues tom mutants in a dose-dependent manner. Error bars, s.d.
Figure 4 NF-kB activation is regulated by Birc2
in endothelial cells and regulates vascular
homeostasis in zebrafish embryos. (a) BIRC2/3
siRNA-transfected HUVECs show a reduction in
IKKa/b and NF-kB phosphorylation and activation
after stimulation for 15 min with TNFa, but not
with IL1b. Anti-tubulin immunoblot serves as
protein control for loading. (b–d) Pictures of
54-hpf Tg(flk1:EGFP)s843;Tg(gata1:DsRed)sd2
embryos treated with 0.1% dimethylsulfoxide
(DMSO) or 100 nM NAI (NF-kB activator
inhibitor) from 15-somite stage onwards.
(c) Chemical inhibition of NF-kB caused severe
hemorrhage that is visible as blood pooling in the
Tg(gata1:DsRed) line, in which all the red blood
cells express DsRed. (d) NAI-treated embryos
also showed vascular regression as seen in the
Tg(flk1:GFP)s843 background. (e) Embryos
from toms805 heterozygote intercrosses injected
at the one-cell stage with the indicated amount
of mRNA encoding zebrafish NEMO. Histogram
shows the percentage of tom mutants identified
72 hpf after injection. NEMO rescues
tom mutants in a dose-dependent manner.
Error bars, s.d.
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blood vessel homeostasis by inducing vascular leakage and causing
endothelial cell integrity defects. These data highlight the specific and
critical role of the Birc2–NF-kB pathway in vascular stability and
endothelial cell survival in vivo.
Vascular cells within a blood vessel are exposed to a unique mixture
of survival (proangiogenic: for example, VEGF, FGF, VE-cadherin,
integrins) and apoptotic (antiangiogenic: for example, Fas, TSP-1,
endostatin) signals produced by the surrounding tissues. Endothelial
cells assimilate and respond to these environmental cues by remaining
viable or committing suicide by initiating apoptosis. Therefore, closely
regulated molecular control of endothelial cell survival, integrity and
apoptosis is essential for both embryonic and adult angiogenesis. By
using a combination of genetic and biochemical methods, we have
shown that Birc2 (cIap1) plays an essential role in regulating endo-
thelial cell survival in the microenvironment of blood vessels in vivo.
In this context, Birc2 appears to function by modulating death-
receptor signaling in endothelial cells, possibly by regulating the
formation and function of TNFR complexes. It is also possible that
Birc2 plays a part in Fas and CD40 receptor complexes and signaling,
whose function in angiogenesis is well established. Although the roles
of IAPs in regulating apoptosis have been extensively studied, the
in vivo function of vertebrate BIRC2 and BIRC3 has remained largely
unknown. The in vivo significance of several in vitro BIRC-protein
interactions has also remained elusive. Our results now identify an
in vivo function for vertebrate BIRC2 and BIRC3 and reveal the
importance of these proteins in vascular biology, specifically in
vascular integrity. Studies of the genetic and biochemical mechanisms
regulating vascular development and integrity are important as means
to better understand the molecular basis of development, as well as to
design new therapeutic strategies for endothelial cell–associated dis-
eases, such as tumor angiogenesis, retinopathies and atherosclerosis.
METHODS
Zebrafish strains, mapping, genotyping and constructs. Embryos and adult
fish were raised and maintained under standard laboratory conditions. We used
the following lines: toms805, Tg(flk1:GFP)s843 and Tg(gata1:DsRed)sd2. We
mapped the tom mutation to linkage group 21 using a set of SSLP markers.
For fine mapping, 1,240 mutant embryos were tested with SSLP markers in the
critical interval (Fig. 2a). toms805 mutants were genotyped by polymerase chain
reaction (PCR) amplification followed by restriction enzyme digestion with SfiI.
We isolated and sequenced birc2 cDNA from wild-type and tom mutant
embryos. Full-length birc2, birc4, cflar and nemo were subcloned into the pCS2+
vector for mRNA injection. We used the QuikChange site-directed mutagenesis
kit (Stratagene) to introduce specific point mutations in birc2. Birc4, Birc2,
Birc2 E66A/R67A and Birc2 H617A cDNAs were also subcloned in pcDNA3-
Flag plasmids for transfection experiments. All these constructs were
transfected in HEK cell lines and tested for comparable levels of expression
(data not shown).
In situ hybridization, morpholinos and mRNA injection and chemical
treatment. Whole-mount in situ hybridization was performed as previously
described10. To generate a birc2 in situ probe, 630 base pairs at the 3¢ end of the
gene were cloned into pCS2+. We used a splicing morpholino against the exon
1–intron 1 junction of birc2 (Supplementary Methods). We injected
Tg(flk1:GFP)s843 embryos at the one-cell stage with 4 ng of morpholino and
assayed them between 48–72 hpf. Embryos from toms805 heterozygote inter-
crosses were injected at the one- or two-cell stage with the indicated amount of
mRNA encoding for the different proteins. We also included a control mRNA
for H2B-cherry (50 pg) in each injection. Injected embryos were scored for
vascular apoptosis and integrity defects at 60–72 hpf and genotyped. We
injected at least 100 eggs for each experimental point. Data are representative
of three independent experiments for each construct. We treated embryos with
the indicated amount of 6-amino-4-(4-phenoxyphenylethylamino)quinazoline
(NAI), BAY11-7082, wedelolactone and Z-IETD-fmk (Calbiochem). As a
control, embryos from the same batch were treated with DMSO. Embryos
were treated from the 15-somite stage until they were harvested for fixation at
the indicated time.
Cell culture, in vitro binding, immunoblot and immunohistochemistry. We
cultured primary human endothelial cells (HUVECs) and HEK293 cells in
appropriate media according to the manufacturer’s protocols (Clonetics and
ATCC). We used the TNT Quick Coupled In vitro Transcription and Transla-
tion kit (Promega) for in vitro translation. Zebrafish TRAF2 were in vitro
translated in the presence of 35S-methionine. For in vitro binding assays,
in vitro–translated products were co-incubated with cell lysates from HEK293T
cells transfected with Flag-tagged wild-type or mutant Birc2, to allow protein-
protein interaction. We immunopurified formed protein complexes using beads
coated with anti-Flag antibodies. After washing to remove unbound proteins,
bound proteins were detected by SDS-PAGE and autofluorography. The ex vivo
ubiquitination assay to examine Birc2 E3 activity was performed as described19.
In the current ubiquitination assay, in vitro translated TRAF2 was added as E3
substrate to the cell lysates and co-immunoprecipitated with Birc2, and then
subjected to the ubiquitination assay. Control, BIRC2 and BIRC3 siRNA were
from siGENOME collection of Dharmacon. We transfected HUVECs with the
same amount of control or BIRC2/3 siRNA with oligofectamine reagent
according to the manufacturer’s protocols (Invitrogen). Cells were then
stimulated with TNFa or IL1b and total cell extracts analyzed for immuno-
blotting. After 48 h, we lysed transfected cells with lysis buffer containing
20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 1% Triton X-100,
20 mM DTT, 10 mM sodium pyrophosphate, 20 mM NaF, 1 mM sodium
orthovanadate and protease inhibitors. We carried out co-immunoprecipita-
tion experiments as previously described19. Protein extracts were prepared
by placing equal numbers (typically 40–70) of animals in 0.5 ml of lysis
buffer (50 mM Tris (pH 8.0), 150 mM NaCl, 1% Triton X-100 and 0.1%
SDS) containing a cocktail of protease and phosphatase inhibitors (Roche)
and sonicating them for 10 s. Insoluble materials were removed by centrifuga-
tion. Proteins were separated by SDS-PAGE gels under reducing conditions,
transferred to nitrocellulose membranes, and stained with antibodies.
Embryos were fixed overnight with 2% paraformaldehyde and embedded in
low melting agarose. We cut embedded embryos with a Leica vibratome into
250 mm sections. Sections were processed in PBDT (1% BSA, 1% DMSO and
0.1% Triton X-100 in PBS, pH 7.3). We mounted processed samples in
Vectashield (Vector Laboratories) and acquired the images using a Zeiss
LSM5 Pascal confocal microscope and Zeiss confocal projection software. We
used the following antibodies and dilutions: rabbit anti-Birc2 (PTG) at 1:1,000
for immunoblotting and 1:100 for immunofluorescence, mouse IgG anti–b-
catenin (Sigma) at 1:100, mouse IgG anti–zona occludin-1 (BD Transduction
Laboratory) at 1:200, rabbit anti-tubulin (Abcam) 1:1000, rabbit anti–active
caspase-3 and mouse anti–caspase-8 (Calbiochem) at 1:100 and phosphoIKKa/b
(ser176/180) and phosphoNF-kB p65 (ser536) (Cell Signaling) at 1:1,000. DNA
was visualized with TO-PRO3 and f-actin with phalloidin (Molecular Probes).
The TUNEL cell death assay was carried out using the ‘‘In Situ Cell Death
Detection Kit’’ TMR red (Roche) according to manufacturer’s instructions.
Note: Supplementary information is available on the Nature Genetics website.
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